B-cell Acute Lymphoblastic Leukemia Clinical Trials in Atlanta, Georgia

3 studies are recruiting for b-cell acute lymphoblastic leukemia in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Winship Cancer Institute Emory University, Atlanta, Georgia

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

2. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

   This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

   Stage

   Phase 2

   Ages

   7 to 25

   Site

   Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia

   Locations

   16 in total

   Run by

   Etan Orgel

   See if you can join NCT05082519 on ClinicalTrials.gov

3. The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

   This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL…

   Stage

   Phase 2

   Ages

   1 to 25

   Site

   Children's Healthcare of Atlanta, Atlanta, Georgia

   Locations

   24 in total

   Run by

   Pediatric Transplantation & Cellular Therapy Consortium

   See if you can join NCT03509961 on ClinicalTrials.gov